TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
IKT

Inhibikase Therapeutics Inc

Healthcare · Biotechnology

2.30$ -0.4% vs. previous close Closing price · As of: Sep 17, 2026

Investor relations

Report Dates

Investor relations overview for Inhibikase Therapeutics Inc (IKT): report dates, earnings surprises, earnings call transcripts and the latest headlines. The next report is scheduled for 08/13/2026.

Next report 08/13/2026
Last report 08/11/2026
Earnings surprise by quarter (%)
Q3 23 · 23.2 % 23 Q4 23 · 24.7 % 23 Q1 24 · 7.6 % 24 Q2 24 · 1.5 % 24 Q3 24 · -35.4 % 24 Q4 24 · -101.7 % 24 Q1 25 · -66.7 % 25 Q2 25 · -37.5 % 25 Q3 25 · 0.0 % 25 Q4 25 · 25.0 % 25 Q1 26 · -5.7 % 26 Q2 26 · -22.2 % 26

EPS estimate beaten

Full history 8 of 32 quarters (25%)
Last 16 quarters 6 of 16 quarters (38%)

Earnings Call Transcripts

Search all transcripts →

No transcripts yet — they will show up here automatically after the next earnings call.

News on This Stock

  • 09/08/2026 Inhibikase Therapeutics, Inc. (IKT): Regulation FD Disclosure; Financial Statements and Exhibits · sec.gov Open ↗
  • 08/26/2026 Inhibikase Therapeutics, Inc. (IKT): Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits · sec.gov Open ↗
  • 08/11/2026 Inhibikase Therapeutics, Inc. (IKT): Results of Operations and Financial Condition; Financial Statements and Exhibits · sec.gov Open ↗
  • 07/29/2026 Inhibikase Therapeutics, Inc. (IKT): Unregistered Sales of Equity Securities; Financial Statements and Exhibits · sec.gov Open ↗
  • 07/23/2026 Inhibikase Therapeutics, Inc. (IKT): Regulation FD Disclosure; Financial Statements and Exhibits · sec.gov Open ↗
  • 07/14/2026 Inhibikase Therapeutics, Inc. (IKT): Other Events; Financial Statements and Exhibits · sec.gov Open ↗

Automatically matched wire and portal stories; external links open the original source.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Transcripts: transcript archive

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?